NTRK1 and hepatocellular carcinoma: Hepatocellular carcinoma (HCC), a highly aggressive malignancy often diagnosed at advanced stages, has limited treatment options.[1] Lenvatinib, a tyrosine kinase receptor inhibitor, represents a frontline therapeutic approach for advanced HCC.[2] However, its limited response rate (24.1%)[3] and emergent resistance development necessitate molecular mechanism exploration to innovate strategies against drug resistance.